Exagen is dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention. Exagen has developed and is commercializing a portfolio of innovative testing products under its AVISE brand, several of which are based on the proprietary Cell-Bound Complement Activation Products, or CB-CAPs, technology. Exagen's goal is to enable providers to improve care for patients through the differential diagnosis, prognosis and monitoring of complex autoimmune and autoimmune-related diseases, including rheumatoid arthritis and lupus.
Company profile
Ticker
XGN
Exchange
Website
CEO
Fortunato Rocca
Employees
Incorporated
Location
Fiscal year end
Sector
Industry (SIC)
Former names
EXAGEN DIAGNOSTICS INC
SEC CIK
XGN stock data
Latest filings (excl ownership)
10-K
2022 FY
Annual report
20 Mar 23
8-K
Exagen Inc. Reports Fourth Quarter and Full Year 2022 Results
20 Mar 23
8-K
Exagen Inc. Elects Tina S. Nova, Ph.D. as Executive Chair of the Board of Directors
23 Jan 23
8-K
Results of Operations and Financial Condition
9 Jan 23
8-K
Cost Associated with Exit or Disposal Activities
5 Dec 22
10-Q
2022 Q3
Quarterly report
21 Nov 22
NT 10-Q
Notice of late quarterly filing
14 Nov 22
8-K
Exagen Inc. Reports Third Quarter 2022 Results
14 Nov 22
8-K
Exagen Announces Appointment of John Aballi as CEO
20 Oct 22
Transcripts
XGN
Earnings call transcript
2022 Q4
20 Mar 23
XGN
Earnings call transcript
2022 Q3
15 Nov 22
XGN
Earnings call transcript
2022 Q2
6 Aug 22
XGN
Earnings call transcript
2022 Q1
12 May 22
XGN
Earnings call transcript
2021 Q4
23 Mar 22
XGN
Earnings call transcript
2021 Q3
13 Nov 21
XGN
Earnings call transcript
2021 Q2
10 Aug 21
XGN
Earnings call transcript
2021 Q1
12 May 21
XGN
Earnings call transcript
2020 Q4
17 Mar 21
XGN
Earnings call transcript
2020 Q3
10 Nov 20
Latest ownership filings
4
Kamal Adawi
3 Mar 23
4
Mark Hazeltine
3 Mar 23
4
Kamal Adawi
1 Mar 23
4
Mark Hazeltine
1 Mar 23
SC 13G/A
RTW INVESTMENTS, LP
14 Feb 23
SC 13G/A
LYTTON LAURENCE W
13 Feb 23
SC 13G/A
Stonepine Capital Management, LLC
13 Feb 23
4
Mark Hazeltine
10 Feb 23
4
Kamal Adawi
10 Feb 23
SC 13G/A
WASATCH ADVISORS INC
9 Feb 23
Financial summary
| Quarter (USD) | Dec 22 | Sep 22 | Jun 22 | Mar 22 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 62.59 mm | 62.59 mm | 62.59 mm | 62.59 mm | 62.59 mm | 62.59 mm |
| Cash burn (monthly) | 2.10 mm | 3.08 mm | 4.83 mm | 3.84 mm | 1.91 mm | 2.68 mm |
| Cash used (since last report) | 5.67 mm | 8.29 mm | 13.01 mm | 10.33 mm | 5.15 mm | 7.21 mm |
| Cash remaining | 56.92 mm | 54.30 mm | 49.58 mm | 52.26 mm | 57.44 mm | 55.38 mm |
| Runway (months of cash) | 27.1 | 17.6 | 10.3 | 13.6 | 30.1 | 20.7 |
Institutional ownership, Q3 2022
26.5% owned by funds/institutions
| 13F holders | Current |
|---|---|
| Total holders | 42 |
| Opened positions | 3 |
| Closed positions | 11 |
| Increased positions | 12 |
| Reduced positions | 14 |
| 13F shares | Current |
|---|---|
| Total value | 76.31 mm |
| Total shares | 13.63 mm |
| Total puts | 0.00 |
| Total calls | 177.50 k |
| Total put/call ratio | – |
| Largest owners | Shares | Value |
|---|---|---|
| NMSIC Co-Investment Fund | 2.31 mm | $26.85 mm |
| Cowen Financial Products | 1.38 mm | $16.10 mm |
| Cowen And | 1.33 mm | $3.60 mm |
| Stonepine Capital Management | 1.27 mm | $3.43 mm |
| Tullis Dickerson Capital Focus Iii | 1.11 mm | $0.00 |
| RTW Investments | 1.05 mm | $2.84 mm |
| Hunt Holdings Limited Partnership | 1.01 mm | $11.76 mm |
| Wasatch Advisors | 1.01 mm | $2.74 mm |
| Silvercrest Asset Management | 507.11 k | $1.37 mm |
| MS Morgan Stanley | 493.65 k | $1.34 mm |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 2 Mar 23 | Mark Hazeltine | Common Stock | Sell | Dispose S | No | No | 0 | 3,667 | 0.00 | 190,205 |
| 2 Mar 23 | Kamal Adawi | Common Stock | Sell | Dispose S | No | No | 2.2993 | 3,667 | 8.43 k | 188,271 |
| 27 Feb 23 | Kamal Adawi | Common Stock | Grant | Acquire A | No | No | 0 | 100,000 | 0.00 | 191,938 |
| 27 Feb 23 | Mark Hazeltine | Common Stock | Grant | Acquire A | No | No | 0 | 100,000 | 0.00 | 193,872 |
| 8 Feb 23 | Mark Hazeltine | Common Stock | Sell | Dispose S | No | No | 2.6924 | 5,821 | 15.67 k | 93,872 |
News
Exagen Earnings Perspective: Return On Capital Employed
21 Mar 23
Nike, Tencent Music Entertainment And 3 Stocks To Watch Heading Into Tuesday
21 Mar 23
Exagen Raises Q1 Revenue Guidance From $8.2M-$9.2M To $9.2M-$9.7M Vs $9.33M Est
20 Mar 23
Exagen Q4 EPS $(0.83) Misses $(0.78) Estimate, Sales $12.84M Beat $8.66M Estimate
20 Mar 23
Earnings Scheduled For March 20, 2023
20 Mar 23
Press releases
Exagen Inc. Reports Fourth Quarter and Full Year 2022 Results
20 Mar 23
Exagen to Announce Fourth Quarter and Full Year Financial Results on March 20, 2023
6 Mar 23
Coya Therapeutics' Expansion Of Exclusive Worldwide Licensing Agreement With ARscience Biotherapeutics Could Have Outsized Impact On Neurodegenerative And Autoimmune Diseases Treatments
16 Feb 23
Exagen Inc. to Participate in the 2023 BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
30 Jan 23
Exagen Inc. Elects Tina S. Nova, Ph.D. as Executive Chair of the Board of Directors
23 Jan 23